DOI: 10.1007/s13311-017-0519-x Pages: 284-297
Article Type: Review

Glioma Subclassifications and Their Clinical Significance

1. University of Utah, Department of Neurology, Clinical Neurosciences Center

2. University of Utah, Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute

3. University of Utah, Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center

Correspondence to:
Howard Colman



The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.

To access the full text, please Sign in

If you have institutional access, please click here

  • Online: Mar 9, 2017

Article Tools